These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11797463)

  • 21. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of uterine leiomyomas and hirsutism with nafarelin.
    Monroe SE; Andreyko J
    J Reprod Med; 1989 Dec; 34(12 Suppl):1029-33. PubMed ID: 2533618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
    McCluggage WG; Bharucha H
    Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of urinary retention caused by uterine leiomyoma with a gonadotropin-releasing hormone agonist: case report and review.
    Chu CM; Dabney L; Hardart A
    Female Pelvic Med Reconstr Surg; 2013; 19(1):52-5. PubMed ID: 23321661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
    Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
    Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pulmonary densities following a hysterectomy, caused by benign metastatic leiomyoma].
    Scheer ML; Slebos DJ; Bogchelman DH; Timens W
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2027-31. PubMed ID: 18825892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
    Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
    Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [GnRH analogues in the management of uterine leiomyoma].
    Matsuo H; Maruo T
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():75-9. PubMed ID: 16689288
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of LH-RH agonists in uterine leiomyoma].
    Maheux R
    J Gynecol Obstet Biol Reprod (Paris); 1990; 19(5):603-6. PubMed ID: 2212519
    [No Abstract]   [Full Text] [Related]  

  • 30. [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review].
    De Falco M; Pollio F; Pontillo M; Ambrosino E; Busiello A; Carbone IF; Ciociola F; Di Nardo MA; Landi L; Di Lieto A
    Minerva Ginecol; 2006 Dec; 58(6):553-60. PubMed ID: 17108883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroids (uterine myomatosis, leiomyomas).
    Lethaby A; Vollenhoven B
    Clin Evid; 2003 Jun; (9):2028-43. PubMed ID: 15366172
    [No Abstract]   [Full Text] [Related]  

  • 33. Fibroids (uterine myomatosis, leiomyomas).
    Lethaby A; Vollenhoven B
    Clin Evid; 2004 Jun; (11):2406-26. PubMed ID: 15652116
    [No Abstract]   [Full Text] [Related]  

  • 34. Medical management of fibroids.
    Sankaran S; Manyonda IT
    Best Pract Res Clin Obstet Gynaecol; 2008 Aug; 22(4):655-76. PubMed ID: 18468953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
    Huang SC; Tang MJ; Cheng YM; Hsu KF; Ho CL; Chou CY
    J Clin Endocrinol Metab; 2003 Oct; 88(10):5009-16. PubMed ID: 14557488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
    Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
    Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
    Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
    Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
    Morris EP; Rymer J; Robinson J; Fogelman I
    Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conservative management for perimenopausal women with uterine leiomyomas using Chinese herbal medicines and synthetic analogs of gonadotropin-releasing hormone.
    Sakamoto S; Mitamura T; Iwasawa M; Kitsunai H; Shindou K; Yagishita Y; Zhou YF; Sassa S
    In Vivo; 1998; 12(3):333-7. PubMed ID: 9706480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis.
    McClean G; McCluggage WG
    Int J Surg Pathol; 2003 Oct; 11(4):339-44. PubMed ID: 14615835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.